FDA approves new drug Rasonque to treat advanced pancreatic cancer

The US FDA has approved Revolution Medicines' groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new hope to those with the deadly cancer. The once-daily pill, to be called Rasonque, was approved for metastatic pancreatic cancer in patients who have received prior treatment or cannot receive combination chemotherapy. The drug is designed to block several forms of the RAS protein, which helps drive tumour growth in many pancreatic cancers. Revolution said the drug is now available in the United States at $39,800 for a 30-day supply. The company added that it would make assistance available as well. When Revolution announced the trial results in April for the drug, it set off a firestorm of demand. The FDA quickly granted early access to it under its compassionate use programme, which allows patients with serious or life-threatening conditions to get experimental treatments outside clinical trials prior to authorisation by the regulator. To display this content from YouTube, you must enable advertisement tracking and audience measurement. One of your browser extensions seems to be blocking ...